Background {#Sec1}
==========

Recently, the capacity of neoplastic cells to evade immunological destruction became an additional checkpoint in assessing the hallmarks of cancer \[[@CR1]\]. T cells play the most important role in this context; the recognition of tumor-associated antigens by healthy T cells allows the activation of a specific anti-tumor immune reaction. CD8+ effector T cells, known as cytotoxic T lymphocytes (CTLs), are the main players in this process. Two receptors, cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD-1), have been actively studied in cancer for their potential roles as inhibitory receptors. Blockage of these receptors by antibodies has been studied in numerous clinical trials with promising results \[[@CR2], [@CR3]\].

PD-1 is a 288-amino acid cell-surface protein. PD-1 binds two ligands, PD-L1 and PD-L2, which negatively regulate the immune response. The expression of PD-L1 (also known as B7-H1) on tumor cells leads to the inhibition of the T cell-mediated immune response against cancer, thereby enabling tumor progression and metastasis \[[@CR4], [@CR5]\].

Expression of PD-L1 has been correlated with poor clinical outcomes in a number of human cancers \[[@CR6]\], including renal cell cancer (RCC) \[[@CR7]\]. As a result, it has been considered a potential predictive biomarker and has inspired new drug development designed to block PD-1.

Immunotherapy was the leading strategy for treating RCC until recently, when targeted inhibitors of the VEGF (Vascular endothelial growth factor) and mTOR pathway began to show promising results. These therapeutic inhibitors increased progression-free and overall survival rates, but failed to show a durable response. Blocking the PD-1-PD-L1 interaction with monoclonal antibodies, however, restores the activity of T cells within the tumor microenvironment and has been shown to result in a significant and sustained antitumor response in clinical trials \[[@CR8]\].

Our aim is to study the PD-L1 expression in RCC clear cell type (RCC-CC) and how that expression correlates with prognostic factors and tumor recurrence.

Methods {#Sec2}
=======

The Institutional Internal Review Board approved this study (process number 1,034,579). We retrospectively analyzed surgical specimens from 148 patients diagnosed with localized (NX-0 M0) RCC-CC who underwent radical or conservative renal surgery (partial nephrectomy or tumor enucleation) between 1988 and 2006 at our institution. Data and adequate material for examination were available for 115 patients, and the clinical and pathological characteristics are shown in Table [1](#Tab1){ref-type="table"}. For staging purposes, lymph node dissection was limited to the hilar region in those who underwent radical nephrectomy. The same surgeon (MS) operated on all patients and all pathological analyses were performed by the same uropathologist (KRML). Patients with systemic metastatic disease at the time of surgery were excluded from the study. For each patient, the analyzed clinical and pathological characteristics included age, gender, symptoms at initial presentation, tumor size, pT stage (2010 TNM classification), Fuhrman nuclear grade, nucleolar grade as recently recommended by International Society of Urological Pathology (ISUP) \[[@CR9]\], coagulative tumor necrosis, and microvascular invasion. Following surgery, all patients appeared for regular follow-up visits based on their staging. Low-risk patients returned for semi-annual physical examinations and routine blood tests in addition to annual chest radiography and abdominal computed tomography. Chest tomography, bone scintigraphy, and brain imaging were conducted in clinically applicable cases.Table 1Clinical and pathological characteristics of 115 patients with renal cell cancer, clear cell type studied for the presence of PD-L1 immune-expression*N*(%)Age (years old) Mean (SD)57.7(11.5)Gender Male91(79.1) Female24(20.9)Tumor size (cm) Mean (SD)4.8(2.9)Tumor stage pT180(69.6) pT28(7.0) pT327(23.4)Metastasis to lymph nodes6(5.2)Fuhrman nuclear grade 125(21.7) 244(38.3) 341(35.7) 45(4.3)Nucleolar grade 122(19.1) 247(40.9) 346(40.0)Microvascular invasion Absent83(72.2) Present32(27.8)Tumor necrosis Absent91(79.1) Present24(20.9)Presentation Incidental76(66.1) Symptoms39(33.9)

The tissue microarray (TMA) was constructed as previously described \[[@CR10]\]. Using a precision mechanical system (Beecher Instruments, Sun Prairie, WI), tissue cylinders with a diameter of 0.6 mm were removed from each patient's paraffin block containing the RCC-CC from specific areas, corresponding to the previously demarcated, most representative areas from respective hematoxylin-eosin-stained slides. These cylinders were transferred with 3-mm intervals to a recipient paraffin block. Next, the tissue microarray recipient block was cut into 3-μm histologic section, and this slide was used for immunohistochemistry. Two tumor samples were collected per patient, because it has been demonstrated that analysis of 2 disks is comparable to the analysis of a whole tissue section in more than 95 % of cases \[[@CR11]\].

Immunohistochemical analysis was performed using BOND III Leica equipment (Leica Biosystems) using the polyclonal antibody anti-PD-L1 (ABCAM) in a 1:25 dilution.

Statistical analysis was performed using SPSS version 19.0 software. Differences between groups were evaluated using a *χ*^2^ test. Time to recurrence was calculated using the Kaplan--Meier method. The differences between the curves were measured using a log-rank test. Two-tailed tests were used and a p*-*value \<0.05 was considered to be significant.

Results {#Sec3}
=======

PD-L1 was diffusely expressed in the cytoplasm and membrane of tumor cells in 65 (56.5 %) of assessed cases. The staining was weak in 29 (44.6 %), moderate in 15 (23.1 %) and strong in 21 (32.3 %) of the cases (Fig. [1](#Fig1){ref-type="fig"}). For statistical analysis, we considered any intensity of staining as positive and compared these results with cases that were completely negative for staining. The univariate analysis showed correlation between PD-L1 expression and higher nuclear Fuhrman grade (*p* = 0.021) and microvascular tumor embolization (*p* = 0.039). The results are expressed in Table [2](#Tab2){ref-type="table"}. Although there was no correlation between PD-L1 expression and any other of the tested negative prognostic factors, in the few cases in which lymph node metastasis was present, PD-L1 was expressed in 67 % of the cases. PD-L1 was also expressed in 83 % of cases that developed distant metastasis and in 65 % of cases that showed tumor recurrence.Fig. 1Photomicrography showing PD-L1 immune-expression in RCC-CC. **a** Positive control, **b** negative control, **c** Positive - score 1, **d** Positive -- score 2, **e** Positive -- score 3Table 2Correlation between PD-L1 expression and prognostic factorsPD-L1 negPD-L1 pos*p*Characteristics (*N* = 115)Age58.257.40.737Gender Female9(37.5)15(62.5)0.507 Male41(45.1)50(54.9)Tumor size (cm)4.55.10.246Presentation Incidental34(44.7)42(55.3)0.704 Symptomatic16(41.0)23(59.0)Fuhrman nuclear grade 1,236(52.2)33(47.8)**0.021** 3,414(30.4)32(69.6)Nucleolar grade 112(54.5)10(45.5)0.207 216(34.0)31(66.0) 322(47.8)24(52.2)Microvascular invasion Absent41(49.4)42(50.6)**0.039** Present9(28.1)23(71.9)Tumor necrosis Absent41(45.1)50(54.9)0.507 Present9(37.5)15(62.5)Tumor stage pT138(47.5)42(52.5)0.188 pT2,312(34.3)23(65.7)Metastasis to lymph nodes Absent48(44.0)61(56.0)0.607 Present2(33.3)4(66.7)Development of distant metastasis Absent49(45.0)60(55.0)0.174 Present1(16.7)5(83.3)Tumor recurrence (*N* = 104) Absent39(44.8)48(55.2)0.468 Present6(35.3)11(64.7)Table 3Clinical and pathological characteristics of patients considering tumor recurrenceTumor recurrence (*N* = 104)No(87)Yes(17)*p*CharacteristicsAge (mean-yo)57.760.10.436Gender Female21(24.1)3(17.6)0.561 Male66(75.9)14(82.4)Tumor size (mean-cm)4.18.6\<0.001Presentation Incidental64(73.6)4(23.5)\<0.001 Symptomatic23(26.4)13(76.5)Fuhrman nuclear grade 1,257(65.5)8(47.1)0.150 3,430(34.5)9(52.9)Nucleolar grade 117(19.5)2(11.8)0.743 236(41.4)8(47.1) 324(39.1)7(41.2)Microvascular invasion Absent70(80.5)5(29.4)\<0.001 Present17(19.5)12(70.6)Tumor necrosis Absent72(82.8)9(52.9)0.007 Present15(17.2)8(47.1)Tumor stage pT170(80.5)5(29.4)\<0.001 pT2,317(19.5)12(70.6)Metastasis to lymph nodes Absent86(98.9)13(76.5)\<0.001 Present1(1.1)4(23.5)PDL1 Negative39(44.8)6(35.3)0.468 Positive48(55.2)11(64.7)

One hundred and four patients were followed for a mean time of 115.7 months. Seventeen (16.3 %) of the followed cases suffered tumor recurrence. Tumor size (8.6 cm vs 4.1 cm; *p* \< 0.001), symptomatic presentation (*p* \< 0.001), microvascular invasion (*p* \< 0.001), tumor necrosis (*p* = 0.007), tumor stage (pT2/pT3 vs pT1, *p* \< 0.001) and the presence of lymph node metastasis (*p* \< 0.001) were all factors that were related to tumor recurrence (Table [3](#Tab3){ref-type="table"}).

We have previously described that the Fuhrman nuclear grade and microvascular tumor invasion are powerful predictors of outcome in RCC \[[@CR12]\]. Considering these two important prognostic factors for localized RCC, we built a Kaplan-Meier curve using these parameters with the addition of PD-L1 expression. Cases were grouped as follows: 1. PD-L1 negative, no microvascular tumor invasion and low Fuhrman nuclear grade; 2. Presence of one of any of these variables; 3. Presence of two of any of these variables; and 4. Presence of all three variables: PD-L1 expression, microvascular tumor invasion and high Fuhrman nuclear grade. The curves are shown in Fig. [2](#Fig2){ref-type="fig"}. There is clearly a higher rate of tumor recurrence in patients who were positive for these three poor prognostic factors (*p* = 0.007).Fig. 2Kaplan-Meier curve of tumor recurrence. The blue line represents tumors negative for PD-L1 with no microvascular tumor invasion and low nuclear grade. The green line represents tumors with one of the following: PD-L1 expression, microvascular tumor invasion, or high nuclear grade. The yellow line represents tumors with two of these variables, and the purple line represents tumors with all three unfavorable prognostic factors (*p* = 0.007)

Fourteen (12.2 %) patients died, 13 (92.9 %) of whom died as a result of RCC progression. PD-L1 was positive in 8 from these 13 (61.5 %) cases (*p* = 0.104). Although the relationship is not statistically significant, the small number of tumor-related deaths may have influenced the negative result.

In conclusion, PD-L1 was diffusely expressed by 56.5 % of the cases related to higher nuclear Fuhrman grade (*p* = 0.021) and microvascular tumor embolization (*p* = 0.039) in univariate analysis.

Discussion {#Sec4}
==========

PD-L1 expression has been studied as a biomarker of response to the new PD-1/PD-L1 inhibitors in different tumors, but its prognostic value is not yet well established.

Our study showed that PD-L1 was expressed in 56.5 % of RCC-CC cases and positive expression was correlated with a higher Fuhrman nuclear grade and microvascular tumor embolization. In addition, PD-L1 analysis provided information about the relationship between tumor outcome and higher rates of tumor recurrence when associated with these two other tested prognostic factors.

In 1999, Dong et al. described PD-L1 as a cell-surface glycoprotein within the B7 family of T-cell co-stimulatory molecules that is constitutively expressed by macrophage-lineage cells \[[@CR13]\]. Since then, studies have shown aberrant expression of PD-L1 in various human cancers, including breast, ovarian, lung, and colon cancer, in addition to lymphoma and melanoma \[[@CR14]\]. Tumor cells that express PD-L1 have been shown to inhibit tumor-specific T-cell-mediated immunity by inducing T-cell apoptosis, impairing cytokine production, and diminishing the cytotoxicity of activated T cells \[[@CR15]\].

There are few reports in the literature evaluating the relationship between PD-L1 expression and clinical prognosis in RCC, and the majority of existing reports relates expression with other known poor prognosis factors and negative outcome.

Thompson et al. were the first to study PD-L1 expression by immunohistochemistry in RCC, finding 24 % of staining associated with adverse pathologic features, including higher tumor stage, greater tumor size, a Fuhrman nuclear grade of 3 or 4, and tumor necrosis \[[@CR16]\]. In addition, by evaluating the expression levels of PD-L1 in tumor cells alone, in lymphocytes alone, or in tumor and/or lymphocytes combined, researchers have shown an association between PD-L1 positivity with aggressive tumor behavior and increased risk of death from RCC \[[@CR17]\].

Choueiri et al. showed that PD-L1 expression is related to shorter survival times in patients with metastatic RCC who were receiving VEGF-targeted agents, therefore arguing that PD-L1 expression should be considered in the design of future clinical trials \[[@CR18]\].

Interestingly a study published by Jilaveanu et al. \[[@CR19]\] compared PD-L1 in 34 cases of primary and metastatic RCC showing no correlation between paired specimens. They advocate that the result of primary tumor regarding PD-L1 expression is not appropriate to predict response to the new PD-L1 inhibitors.

In non-clear cell RCC patients with PD-L1 tumor expression is associated with higher tumor stage and grade and worse clinical outcomes \[[@CR20]\].

In breast cancer, PD-L1 was upregulated in 20 % of cases and was related to poor-prognostic features such as tumor size, high grade, estrogen and progesterone negativity, Her2/Neu positivity and higher rates of cell proliferation, although upregulation of PD-L1 was not associated with survival of patients in this study \[[@CR21]\].

In gastric cancer, PD-L1 was positively expressed in 50 % of cases associated with higher T stage, lymph-node metastasis and overall survival \[[@CR22]\].

A meta-analysis study of non-small cell lung cancer indicated that PD-L1 expression is associated with tumor differentiation and lower overall patient survival \[[@CR23]\].

The fact that we used a TMA to indicate PD-L1 expression should be a point of criticism; however, in studies of other tumor markers, the representation of two cores has been shown to generally be similar to a whole tissue fragment, with the advantage of standardization in the immunohistochemistry reaction \[[@CR11]\]. The small number of cases, particularly the small number of cancer deaths, may reflect some percentage of error in TMA-based PD-L1 analysis, which may explain the absence of a positive result regarding PD-L1 expression and tumor prognosis in this statistical analysis.

Conclusion {#Sec5}
==========

In conclusion, this report confirms, using immunohistochemistry, that PD-L1 expression represents a new marker of prognosis in RCC-CC.
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